Iovance Biotherapeutics (NASDAQ:IOVA) experienced a remarkable surge on Thursday, with shares climbing 43.1% to close at $6.21 after touching a 52-week high of $6.39. The rally extended into Friday's premarket session, with shares trading at $6.24. This dramatic move came on the heels of the company's second-quarter earnings report, which showcased record revenue and a significant improvement in profitability metrics.
The company reported second-quarter revenue of $99.3 million, a 14% increase over the initial consensus estimate of $87.1 million. The performance was largely driven by Amtagvi, the company's cell therapy for melanoma, which generated approximately $91 million in sales, surpassing the company's guidance range of $79 million to $81 million. Proleukin, a legacy product, contributed nearly $9 million to the quarter's revenue.
Investors were particularly encouraged by the company's manufacturing efficiency gains. Revenue increased by $27.9 million quarter-over-quarter, while cost of sales rose just $1.1 million. This translated into a gross margin of 56.1% (excluding depreciation and amortization), up from 40.5% in the first quarter and 18.5% in the year-ago period. The data suggests that fixed manufacturing costs are being spread across a growing number of patient treatments, marking a pivotal turning point for the company's operational leverage.
Interim CEO Frederick Vogt highlighted the significance of the results, stating, "Second-quarter revenue hit an all-time high of $99.3 million with a gross margin of 56%." The company is now reassessing its full-year revenue guidance of $350 million to $370 million, with a revised outlook expected in the third quarter. If the second-quarter pace continues, projected 2026 revenue would reach approximately $369.4 million, near the upper end of the current range.
The company's commercial expansion continues apace, with over 95 approved treatment centers across the U.S., Canada, and Australia, and a target of at least 110 by year-end. Unaided physician recognition has nearly tripled over the past year, and manufacturing turnaround times are holding at 31 days or fewer. These factors are expected to support sustained growth in patient adoption and revenue.
Financially, Iovance ended June with approximately $304 million in cash, investments, and restricted cash, which management projects will fund operations through the second half of 2028. Operating cash usage in the first half was $132.9 million, offset by $148.1 million in net proceeds from common stock issuance. The company's weighted-average shares outstanding rose 34.6% year-over-year to 450.2 million, reflecting ongoing equity financing activities.
Analyst sentiment remains bullish, with four of five analysts surveyed by Google Finance issuing Buy ratings over the past three months. The average price target stands at $9.75, implying a potential 57% upside from Thursday's closing price. Notable targets include Barclays' Etzer Darout at $13, Mizuho's Salim Syed at $10, and H.C. Wainwright's Joseph Pantginis at $9. However, UBS's David Dai maintains a Hold rating with a $4 target, and Goldman Sachs' Andrea Newkirk has a Sell rating with a $2 target, highlighting the wide divergence in views.
Upcoming catalysts could further drive the stock. Pivotal lung-cancer cohorts are nearing enrollment completion, with a data update anticipated in the fourth quarter and a regulatory filing targeted for 2027. Initial sarcoma results showed a 50% response rate in the first six evaluable patients, and the FDA has granted Fast Track status. More comprehensive findings are expected at the ESMO meeting from October 23-27, though the small early cohort limits definitive conclusions.
Risks remain, notably Amtagvi's heavy concentration, accounting for roughly 92% of quarterly revenue. The company's reliance on a single product underscores the importance of pipeline diversification. Additionally, the stock's volatility and the ongoing need for equity financing are factors investors should monitor. The broader biotech sector saw modest gains, with the SPDR S&P Biotech ETF (NYSEARCA:XBI) advancing 1.0%, while the Nasdaq Composite edged down 0.1%.
